GM-CSF After High-Dose Melphalan in Advanced Colon Cancer
Author Information
Author(s): W.P. Steward, J.H. Scarffel, L.Y. Dirix, J. Chang, J.A. Radford, E. Bonnem, D. Crowther
Primary Institution: Christie Hospital, Manchester, UK
Hypothesis
Can GM-CSF reduce the toxicity of high-dose melphalan in patients with advanced colon cancer?
Conclusion
GM-CSF can significantly increase white blood cell counts without toxicity and may reduce the duration of neutropenia and thrombocytopenia after high-dose melphalan.
Supporting Evidence
- One complete and two partial remissions were observed, resulting in a 33% response rate.
- The median duration of neutropenia was 14 days, similar to historical data.
- GM-CSF was administered without any observed toxicity.
Takeaway
This study tested a medicine called GM-CSF to help cancer patients recover faster after strong chemotherapy. It worked well without causing harm.
Methodology
Patients received GM-CSF as a continuous intravenous infusion followed by high-dose melphalan, with monitoring of white blood cell counts and response to treatment.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
{"median_age":47,"gender_ratio":"5:4","performance_status":{"median":80,"range":"70-90"}}
Want to read the original?
Access the complete publication on the publisher's website